Document Detail

MedLine Citation:
PMID:  17925887     Owner:  NLM     Status:  MEDLINE    
Tamibarotene is a new synthetic retinoid drug recently approved for relapsed or refractory acute promyelocytic leukemia (APL) in Japan. It is a specific agonist for retinoic acid receptor alpha/beta. Compared to all-trans retinoic acid (ATRA), a natural retinoid indicated for a first-line treatment of APL, tamibarotene is chemically more stable and several times more potent as an inducer of differentiation in promyelocytic leukemia cells. In contrast to ATRA, whose plasma concentration declines considerably during daily administration, tamibarotene sustains plasma level probably due to a lower affinity for cellular retinoic acid binding protein. Furthermore, adverse side effects were milder than those of ATRA in clinical trials. Clinical trials held in Japan showed that tamibarotene had efficacy in APL patients who had relapsed from ATRA-induced complete remission. Recently, better understanding of the various mechanisms of action of retinoids has stimulated great interest in its potential use for treatment of various diseases. Tamibarotene is being investigated for treatment of multiple myeloma and Crohn's disease in clinical trials. This review focuses on tamibarotene's mechanisms of action, chemical properties, pharmacokinetics and its use in APL as well as its potential use in various disorders.
Ishido Miwako; Hiroyuki Kagechika
Related Documents :
15927497 - An ascidian homologue of the gonadotropin-releasing hormone receptor is a retinoic acid...
12419957 - Taraxinic acid, a hydrolysate of sesquiterpene lactone glycoside from the taraxacum cor...
23472037 - Chemical composition and amino acid profiles of goose muscles from native polish breeds.
3534017 - All-trans-retinoic acid and cutaneous cancers.
15850717 - N-6 polyunsaturated fatty acids confer hemodynamic stability in an experimental model o...
1739747 - Purification and nh2-terminal amino acid sequences of human and rat kidney fatty acid o...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Drugs of today (Barcelona, Spain : 1998)     Volume:  43     ISSN:  1699-3993     ISO Abbreviation:  Drugs Today     Publication Date:  2007 Aug 
Date Detail:
Created Date:  2007-10-10     Completed Date:  2008-01-24     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101160518     Medline TA:  Drugs Today (Barc)     Country:  Spain    
Other Details:
Languages:  eng     Pagination:  563-8     Citation Subset:  IM    
Copyright Information:
(c) 2007 Prous Science.
R&R Inc., Tokyo, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / adverse effects,  pharmacology,  therapeutic use*
Benzoates / adverse effects,  pharmacology,  therapeutic use*
Controlled Clinical Trials as Topic
Drug Evaluation, Preclinical
Leukemia, Promyelocytic, Acute / drug therapy*
Tetrahydronaphthalenes / adverse effects,  pharmacology,  therapeutic use*
Reg. No./Substance:
0/Antineoplastic Agents; 0/Benzoates; 0/Tetrahydronaphthalenes; 94497-51-5/Am 80

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Recombinant human serum albumin.
Next Document:  Role of genetic polymorphisms related to neurotransmitters and cytochrome P-450 enzymes in response ...